Community pharmacies must be involved in future planning for public health emergencies, especially in cases where a quick response is needed such as the Covid-19 pandemic, a European-wide research has recommended.
The project, co-led by the University of Huddersfield professor Zaheer-Ud-Din Babar in medicines and healthcare, focuses on how community pharmacies dealt with the pandemic, covering 31 pharmacy interventions on Covid-19 in 32 countries in Europe.
The interventions include prevention, response, and recovery measures. It also covers improved access to medicines, expanded powers granted to pharmacies, rapid antigen testing, along with Covid-19 vaccination.
Community pharmacists in the US, Canada, and Australia have been engaged in pandemic prevention, preparedness, and response strategic guidance after the 2009 flu pandemic.
The aim of the research is to map the current reported practice and trends and review the pharmacies' intervention in Europe.
The Labour Party's election manifesto, unveiled with a focus on bolstering community pharmacy services and enhancing localised healthcare, has sparked
responses from key pharmacy bodies across England.
A standout pledge within the manifesto is the commitment to establish a Community Pharmacist Prescribing Service, aimed at granting more pharmacists independent
prescribing rights.
This initiative is viewed as pivotal in recognising the clinical capabilities of pharmacists and their potential to alleviate pressures within primary care.
Additionally, Labour's plan advocates for broader healthcare access improvements, including enabling opticians to directly refer patients to specialist services
and expanding self-referral options where suitable.
The manifesto also introduces proposals to trial Neighbourhood Health Centres, designed to consolidate various healthcare services under one roof, such as family
doctors, district nurses, and mental health specialists.
In a collaborative effort to combat the escalating threat of antimicrobial resistance (AMR), UWE Bristol and Bedminster Pharmacy have secured grant funding
from the UKRI Regional Innovation Fund (RIF) for a groundbreaking 4-month project.
This initiative aims to revolutionise antimicrobial stewardship (AMS) practices at the community pharmacy level, addressing the pressing need for evidence-based
approaches in tackling AMR.
With antibiotic misuse contributing significantly to the rise of AMR, the project underscores the vital role of community pharmacies in promoting responsible
antibiotic use.
Mr Ade Williams, Superintendent Pharmacist at Bedminster Pharmacy, emphasised the significance of this endeavour, stating:
The Leverhulme Trade Charities Trust (LTCT) has announced the launch of a new scheme to support pharmacists and their families during the back-to-school period.
Opening at 9 am on Tuesday, June 18, 2024, the 'School Essentials Grant' is designed to alleviate financial pressure for people working in community pharmacies
with young children during one of the most costly times of the year.
The scheme will see the charity provide up to £100,000 of support to pharmacists in need of financial aid.
Eligible families can apply online to receive £150 per school-age child, up to a maximum of three children per household. This grant can be used for essential
expenses such as new school uniforms, stationery, or travel passes.
The application window will remain open until September 1 or until the fund has been depleted. Hence, families are encouraged to apply as soon as they can.
Department of Health and Social Care (DHSC) has updated the final price concessions for June 2023, following a discussion by Community Pharmacy England
regarding medicine pricing issues reported by pharmacy owners (its members).
A price concession only applies for the month it is granted; any prices agreed for concessions requested late in the month will roll over into the following month.
Community Pharmacy England encouraged pharmacies to report any problems obtaining a Part VIII product at or below the stated Drug Tariff price, using the online
feedback form on the Community Pharmacy England website along with full details of the supplier and price paid for any products sourced above the Drug Tariff price.
The association will investigate the extent of the problem and, if appropriate, discuss the issue with DHSC.
The Royal Pharmaceutical Society (RPS) has awarded Professor Abdul Basit with the RPS Harrison Memorial Medal for an outstanding contribution to advancing
pharmaceutical science.
Professor Basit graduated with a First Class Honours degree in Pharmacy from the University of Bath, and received his PhD from The School of Pharmacy, University
of London.
Currently in position as Professor of Pharmaceutics at the UCL School of Pharmacy, he is internationally recognised for leading in the field of drug delivery,
microbiome medicines, three-dimensional printing of pharmaceuticals and digital health. He has also founded three start-up companies.
Professor Basit has an impressive track record of publications, and a lifetime grant and investment income of over £100million pounds. His research has led to
a series of transformative drug delivery systems, translated into the design of new technologies and improved therapies, many of which have been commercialised
and launched worldwide including a new treatment for inflammatory bowel disease. To date, more than a million patients have benefited from inventions created and
developed in the Basit Research Group.
Boots UK has agreed to grant a five per cent pay increase to its pharmacists following a collaborative agreement with the Pharmacists' Defence
Association (PDA). This raise acknowledges the unique market conditions faced by pharmacists in the community pharmacy sector, Boots UK and PDA said in a
joint statement on Oct. 9.
According to the statement, the pay increase applies to all pharmacists within the PDA Union's bargaining unit, except for those who joined or received a pay
raise after August 2023. Moreover, trainee pharmacists or those not meeting performance standards are not eligible for the raise.
Additionally, pharmacists and store managers will receive a pro-rata, one-time non-consolidated payment of £750 in August 2024. This payment serves as recognition
for their dedication to establishing and providing new core and advanced NHS services, particularly in light of the substantial changes anticipated in the upcoming
year, the joint statement said.
The services include new medicines, hypertension, contraception, and common conditions services in England, the clinical community pharmacy service in Wales, and
the Pharmacy First services in Scotland and Northern Ireland.
The price concession for Atorvastatin 80mg has been increased to £3.91 from the previously set £3.45 for prescriptions dispensed in July, the Community Pharmacy
England has said. The Department of Health and Social Care additionally introduced a concession price of £3.38 for Atorvastatin 20mg.
"In July, our Dispensing and Supply Team experienced an unusually high influx of reports from pharmacies struggling to acquire Atorvastatin 80mg tablets at the
listed Drug Tariff price," said CPE.
CPE requested a price concession early in the month. However, after extended discussions, an agreement on the price wasn't reached. Consequently, on July 31st, the
DHSC imposed a concession of £3.45.
Addressing enduring pharmacy concerns over the pricing, CPE intensified advocacy with DHSC. This endeavour resulted in the revision of the Atorvastatin 80mg tablet
concession price to £3.91 for prescriptions submitted and dispensed in July.
According to CPE, this adjusted price sufficiently covers costs as reported by the majority of pharmacy owners.
However, DHSC has refrained from modifying concessionary prices for the other two requested lines by CPE. DHSC communicated that their team's data collection for
July, employing real-time sales and volume data, was incongruent with the adjustment of these prices, CPE further said.
The Pharmaceutical Services Negotiating Committee (PSNC) has expressed its concerns over sustained pressures on medicines supply that are having a very
serious impact on community pharmacy teams and their patients.
It has asked contractors and their teams to continue using its regular reporting tools to help them demonstrate the scale of the problems to the Department of
Health and Social Care (DHSC) and to support escalations as needed.
The committee said: "The sustained increases in price concessions that we have seen so far in 2022 - with more than 100 concessions being granted in some months -
show no signs of abating, and we know that many pharmacies now find themselves in a critical situation trying to source medicines in timely manner and facing
significant financial risk due to greater uncertainty around expected reimbursement prices for a large number of medicines."
"We know that some concessions being imposed by the Department do not match contractors' experience on the ground, and we would ask all contractors to continue
reporting pricing issues to us on a regular basis to support our representations: Report product over Drug Tariff price."
The Department of Health and Social Care (DHSC) has revised concession prices for four products and confirmed three further price concessions for May 2024.
This announcement comes in response to representations made by Community Pharmacy England (CPE) on behalf of community pharmacy owners
Concession prices have been redetermined for Ezetimibe 10mg tablets, Quetiapine 100mg tablets, Quetiapine 150mg tablets and Quetiapine 200mg tablets.
Here are the newly granted concessions:
Nicorandil 10mg tablets (60 tablets): £5.05
Nicorandil 20mg tablets (60 tablets): £9.30
Pregabalin 75mg capsules (56 capsules): £1.54
The revised prices will be applicable to prescriptions submitted for payment during the dispensing month of May 2024, and do not apply to June 2024 prescriptions,
the CPE noted.
Six pharmacists based in Scotland were acknowledged by the profession this week during a celebratory event held at the home of Scottish pharmacy, the RPS
building on Melville Street, Edinburgh.
Four pharmacists have been officially conferred with Fellowships of RPS for their significant contributions to the practice of pharmacy. The recipients are:
Richard Lowrie
Lynn Morrison
Deborah Steven
Audrey Thompson
Two pharmacists, Katherine Davidson and Emily Kennedy, have attained accreditation as consultant pharmacists. This designation is granted in recognition of their
demonstrated expertise at a senior level, spanning clinical practice, leadership, research, and education, RPS said in a statement.
Essential Pharma, an international speciality pharma group, has procured an establishment and manufacturing licences in Switzerland and Malta.
Following a successful inspection by Swissmedic, the company has been granted an establishment licence in Switzerland, which will allow the company to significantly
enhance its supply chain efficiency for a wide range of important medicinal products. It will apply to transactions for both finished and unfinished pharmaceuticals,
allowing importing, exporting, wholesaling and trading abroad.
Essential Pharma has also received a manufacturing and importation authorisation (MIA) in Malta, following a successful Good Manufacturing Practice (GMP) inspection
by the Malta Medicines Authority.
The MIA will allow the company to import medicinal products into the European Union where manufacturing has taken place in a third country. This will allow greater
flexibility in how the business manages the flow of medicines across its territories.
These approvals strengthen the company's geographical expansion, improve its operational efficiencies, and enhance its offering as a global business partner. They
will also provide new strategic opportunities for the company and will play a fundamental role in driving value creation through functional improvements to scale
and productivity.
Nine more new products have been classed as 'Drugs for which Discount is Not Deducted' (DND) from 1 July 2022, announced Department of Health and Social
Care (DHSC).
This takes the total number of products granted DND status over the past 2 years to over 500 following checks made by the Pharmaceutical Services Negotiating
Committee.
The Committee had made an application to DHSC and NHSBSA for the following 9 products to be added to the DND list of Individual items to which the discount
deduction scale will no longer apply from July 2022:
Fludrocortisone 50micrograms/5ml oral suspension (Group)
Lorazepam 1mg/5ml oral suspension (Group)
Lorazepam 500micrograms/5ml oral suspension (Group)
Zopiclone 3.75mg/5ml oral solution (Group)
Zopiclone 7.5mg/5ml oral solution (Group)
GA explore5 oral powder 12.5g sachets
HCU explore5 oral powder 12.5g sachets
MSUD explore5 oral powder 12.5g sachets
TYR explore5 oral powder 12.5g sachets
The DND list is updated monthly by the DHSC and includes grouped and individual items. Individual items are separately listed in Part II of the Drug Tariff.
Healthcare reform emerged as a cornerstone of the Labour Party's manifesto leading up to the recent general election. A standout pledge was the establishment
of a Community Pharmacist Prescribing Service, aimed at granting pharmacists independent prescribing rights where clinically suitable. This initiative is seen as a
positive step in addressing critical challenges within the National Health Service (NHS).
Numark Chairman Harry McQuillan praised Labour's recognition of pharmacists' role in patient care through expanded prescribing rights.
"Let's be honest, pharmacists are an underutilised resource within the healthcare system. We possess extensive training and expertise, yet our full potential
hasn't always been acknowledged.
"By harnessing pharmacists expanded prescribing rights, Labour is acknowledging our significant role in patient care. This initiative aims to recognise our skills
and enhance patient care, ensuring quicker access to necessary treatments," he said.
However, he pointed out that the concept requires further exploration, as the rights to prescribe are already granted through the recent change to undergraduate
training that incorporates prescribing.